Terms: = Germ cell tumor AND BRAF, MGC126806, 673, ENSG00000157764, MGC138284, RAFB1, P15056, B-raf 1, BRAF1, B-raf1 AND Clinical Outcome
111 results:
1. Treatment evaluation by volumetric segmentation in pediatric optic pathway glioma: evaluation of the effect of bevacizumab on intra-tumor components.
Bennebroek CA; Schouten CR; Montauban-van Swijndregt MC; Saeed P; Porro GL; Pott JWR; Dittrich ATM; Oostenbrink R; Schouten-van Meeteren AY; de Jong MC; de Graaf P
J Neurooncol; 2024 Jan; 166(1):79-87. PubMed ID: 38150061
[TBL] [Abstract] [Full Text] [Related]
2. Presumed Pathogenic germ Line and Somatic Variants in African American Thyroid Cancer.
Hurst ZA; Liyanarachchi S; Brock P; He H; Nabhan F; Veloski C; Toland AE; Ringel MD; Jhiang SM
Thyroid; 2024 Mar; 34(3):378-387. PubMed ID: 38062767
[No Abstract] [Full Text] [Related]
3. Intratumoural and systemic inflammation as predictors for treatment response in braf-mutated melanoma patients under targeted therapies.
Gambichler T; Iordanou M; Becker JC; Susok L
Melanoma Res; 2024 Feb; 34(1):80-83. PubMed ID: 37924529
[TBL] [Abstract] [Full Text] [Related]
4. Whole-exome sequencing reveals mutational profiles of anorectal and gynecological melanoma.
Sun W; Liu K; Zhou H; Zhao F; Dong Y; Xu Y; Kong Y; Wang M; Cheng X; Chen Y
Med Oncol; 2023 Oct; 40(11):330. PubMed ID: 37831226
[TBL] [Abstract] [Full Text] [Related]
5. Role of gene sequencing in classifying struma ovarii: braf p.G469A mutation and TERT promoter alterations favour malignant struma ovarii.
Neyrand S; Trecourt A; Lopez J; Just PA; Descotes F; Borson-Chazot F; Ray-Coquard I; Decaussin-Petrucci M; Devouassoux-Shisheboran M
Histopathology; 2024 Jan; 84(2):291-300. PubMed ID: 37771077
[TBL] [Abstract] [Full Text] [Related]
6. Molecular Features of Resected Melanoma Brain Metastases, clinical outcomes, and Responses to Immunotherapy.
Vasudevan HN; Delley C; Chen WC; Mirchia K; Pan S; Shukla P; Aabedi AA; Nguyen MP; Morshed RA; Young JS; Boreta L; Fogh SE; Nakamura JL; Theodosopoulos PV; Phillips J; Hervey-Jumper SL; Daras M; Pike L; Aghi MK; Tsai K; Raleigh DR; Braunstein SE; Abate AR
JAMA Netw Open; 2023 Aug; 6(8):e2329186. PubMed ID: 37589977
[TBL] [Abstract] [Full Text] [Related]
7. brafV600 variant allele frequency predicts outcome in metastatic melanoma patients treated with braf and MEK inhibitors.
Mandalà M; Palmieri G; Ludovini V; Baglivo S; Marasciulo F; Castiglione F; Gili A; Osella Abate S; Rubatto M; Senetta R; Avallone G; Ribero S; Romano L; Pimpinelli N; de Giorgi V; Roila F; Pisano M; Casula M; Manca A; Sini MC; Massi D; Quaglino P;
J Eur Acad Dermatol Venereol; 2023 Oct; 37(10):1991-1998. PubMed ID: 37335879
[TBL] [Abstract] [Full Text] [Related]
8. lncRNA TRHDE-AS1 Correlated with Genomic Landscape and clinical outcome in Glioma.
Xie J; Lin Y; Li Y; Fang A; Li X; Wang S; Li W
Genes (Basel); 2023 May; 14(5):. PubMed ID: 37239411
[TBL] [Abstract] [Full Text] [Related]
9. Combined PD-1, braf and MEK inhibition in braf
Tian J; Chen JH; Chao SX; Pelka K; Giannakis M; Hess J; Burke K; Jorgji V; Sindurakar P; Braverman J; Mehta A; Oka T; Huang M; Lieb D; Spurrell M; Allen JN; Abrams TA; Clark JW; Enzinger AC; Enzinger PC; Klempner SJ; McCleary NJ; Meyerhardt JA; Ryan DP; Yurgelun MB; Kanter K; Van Seventer EE; Baiev I; Chi G; Jarnagin J; Bradford WB; Wong E; Michel AG; Fetter IJ; Siravegna G; Gemma AJ; Sharpe A; Demehri S; Leary R; Campbell CD; Yilmaz O; Getz GA; Parikh AR; Hacohen N; Corcoran RB
Nat Med; 2023 Feb; 29(2):458-466. PubMed ID: 36702949
[TBL] [Abstract] [Full Text] [Related]
10. Identification of a miRNA-based non-invasive predictive biomarker of response to target therapy in braf-mutant melanoma.
Ruggiero CF; Fattore L; Terrenato I; Sperati F; Salvati V; Madonna G; Capone M; Valenti F; Di Martino S; Mandoj C; Liguoro D; Castaldo V; Cafaro G; Simeone E; Vanella V; Russillo M; Conti L; Cuda G; Giannarelli D; Ascierto PA; Mancini R; Ciliberto G
Theranostics; 2022; 12(17):7420-7430. PubMed ID: 36438490
[No Abstract] [Full Text] [Related]
11. The A to I editing landscape in melanoma and its relation to clinical outcome.
Amweg A; Tusup M; Cheng P; Picardi E; Dummer R; Levesque MP; French LE; Guenova E; Läuchli S; Kundig T; Mellett M; Pascolo S
RNA Biol; 2022 Jan; 19(1):996-1006. PubMed ID: 35993275
[TBL] [Abstract] [Full Text] [Related]
12. Single-cell Transcriptomic Analysis Reveals the Crosstalk Propensity Between the tumor Intermediate State and the CD8+ T Exhausted State to be Associated with clinical Benefits in Melanoma.
Zhu J; Yan M; Yan H; Xu L; Jiang Z; Liao G; Zhou Y; Liu W; Liang X; Li X; Xiao Y; Zhang Y
Front Immunol; 2022; 13():766852. PubMed ID: 35903095
[TBL] [Abstract] [Full Text] [Related]
13. Appraisal of clinicopathological prognosticators in advanced acral lentiginous melanoma with characterization of PD-L1 and CD8/CD4 immunoprofiles.
Chuang IC; Jang CS
Jpn J Clin Oncol; 2022 Sep; 52(9):975-981. PubMed ID: 35662346
[TBL] [Abstract] [Full Text] [Related]
14. Can a signature molecular-profile define disparate survival in braf-positive Gliosarcoma and identify novel targets for therapeutic intervention?
Gandhi P; Khare R; Garg N; Mishra J
J Cancer Res Ther; 2022; 18(1):224-230. PubMed ID: 35381788
[TBL] [Abstract] [Full Text] [Related]
15. Real-world data on melanoma brain metastases and survival outcome.
Pedersen S; Møller S; Donia M; Persson GF; Svane IM; Ellebaek E
Melanoma Res; 2022 Jun; 32(3):173-182. PubMed ID: 35256571
[TBL] [Abstract] [Full Text] [Related]
16. Antifibrotic drugs as therapeutic tools in resistant melanoma.
Sanchez-Laorden B; Nieto MA
EMBO Mol Med; 2022 Mar; 14(3):e15449. PubMed ID: 35156326
[TBL] [Abstract] [Full Text] [Related]
17. High-grade glioma with pleomorphic and pseudopapillary features (HPAP): a proposed type of circumscribed glioma in adults harboring frequent TP53 mutations and recurrent monosomy 13.
Pratt D; Abdullaev Z; Papanicolau-Sengos A; Ketchum C; Panneer Selvam P; Chung HJ; Lee I; Raffeld M; Gilbert MR; Armstrong TS; Pytel P; Borys E; Klonoski JM; McCord M; Horbinski C; Brat D; Perry A; Solomon D; Eberhart C; Giannini C; Quezado M; Aldape K
Acta Neuropathol; 2022 Mar; 143(3):403-414. PubMed ID: 35103816
[TBL] [Abstract] [Full Text] [Related]
18. Sensitivity of treatment-free survival to subgroup analyses in patients with advanced melanoma treated with immune checkpoint inhibitors.
Mantia CM; Werner L; Stwalley B; Ritchings C; Tarhini AA; Atkins MB; McDermott DF; Regan MM
Melanoma Res; 2022 Feb; 32(1):35-44. PubMed ID: 34855329
[TBL] [Abstract] [Full Text] [Related]
19. A biomarker panel predicts recurrence-free survival in ulcerated primary cutaneous melanoma.
Falkenius J; Keskitalo J; Kanter L; Johansson H; Höiom V; Hansson J; Egyhazi Brage S
Acta Oncol; 2022 Jan; 61(1):14-21. PubMed ID: 34694198
[TBL] [Abstract] [Full Text] [Related]
20. Skull Base tumors: Neuropathology and clinical Implications.
Bi WL; Santagata S
Neurosurgery; 2022 Mar; 90(3):243-261. PubMed ID: 34164689
[TBL] [Abstract] [Full Text] [Related]
[Next]
